Bill C-97, An Act to implement certain provisions of the budget tabled in Parliament on March 19, 2019 and other measures was introduced in the House of Commons on April 8, 2019, and includes proposed amendments to the Food and Drugs Act to introduce a new framework for “Advanced Therapeutic Products”, including a new licensing framework.
The proposed amendments define an “Advanced Therapeutic Product” as a product or class of products set out in Schedule G. Thus far, Schedule G does not contain any entries, but the proposed amendments allow the Minister to make additions to Schedule G if the Minister believes the product or class of products “represent an emerging or innovative technological, scientific or medical development”.
It is unclear what the full details and scope of this framework will encompass, however it is expected that advanced therapeutic products may include regulation of newer technologies such as cell and gene therapies, 3D printing and novel drug delivery methods. The proposed amendments align with the What we heard: A summary of scanning and consultations on what’s next for health product regulation report issued by Health Canada in March 2019. The report identifies various emerging technologies that Health Canada will be considering further and which Health Canada recognizes are challenging current regulatory classification schemes.
Related Publications & Articles
-
Canada’s Drug Agency releases 2025 Watch List highlighting AI technologies in health care
On March 25, 2025, Canada’s Drug Agency published its annual Watch List, which identifies technologies with the most potential to transform health systems and shape the future of health care in Canada...Read More -
Health Canada publishes Guide to the precision regulating authorities under the Food and Drugs Act
In March 2025, Health Canada published a Guide to the precision regulating authorities under the Food and Drugs Act.Read More -
Health Canada consultation on revised biosimilar guidance: no requirement for comparative clinical efficacy and safety trials
On June 10, 2025, Health Canada launched a consultation on its Draft Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs which includes numerous proposed revisions...Read More